en.Wedoany.com Reported - Optellum has announced that its clinical sites have exceeded 250, with over 3 million cases analyzed cumulatively in the field of AI-driven lung cancer diagnosis. The company is dedicated to providing healthcare systems and clinical care teams with more efficient tools for lung nodule identification, prioritization, and management. This commercial progress has been supported by multiple market collaborations, including a partnership with Bristol Myers Squibb in the United States, as well as collaborations with the National Health Service (NHS) and Intuitive Surgical in the United Kingdom, aimed at advancing end-to-end AI and robotic lung cancer diagnosis and treatment pathways. Additionally, deployments at leading healthcare institutions such as Penn Medicine, Vanderbilt University Medical Center, and Oxford University Hospitals—both new and existing customers—reflect this growth momentum.
Optellum's scale of impact is accelerating, now helping one patient every 14 seconds. The company has launched the world's first FDA-cleared, CE-marked, and Medicare-reimbursed imaging-based lung cancer risk stratification AI solution—Lung Cancer Prediction AI (LCP), corresponding to CPT codes 0721T and 0722T. LCP AI aims to reduce diagnostic uncertainty caused by indeterminate lung nodules, ensuring that high-risk nodules are not missed. Furthermore, the comprehensive Virtual Nodule Clinic (VNC) solution supports clinical guideline-compliant decision-making, proven to improve clinician efficiency while reducing the time for patients to reach recommended treatment (Hill NR et al., BMJ Open Respiratory Research, 2025).
This growth reflects a shift in thoracic care toward evidence-based innovative applications. Optellum is continuously expanding its end-to-end AI-driven lung health platform, LungOS, which is powered by the world's first chest CT foundation model built specifically for real-world precision lung care. This foundation model is the only one utilizing DART, the world's largest lung cancer CT dataset. LungOS integrates VNC with triage and detection modules (including text-based patient finding and patient safety net, with product availability varying by region), diagnostic support modules (available in the US, EU/UK, and Australia), and treatment guidance modules (pending, for research use only). Optellum also plans to expand its clinical suite with the upcoming LungDetect feature, set to launch in Europe, aimed at simplifying and accelerating nodule identification and characterization.
Dr. Johnathan Watkins, CEO of Optellum, stated that the team is proud to help more healthcare systems and clinicians deliver timely, life-saving care to patients. Reaching 250 sites and analyzing millions of cases annually is a testament to the team's dedication and the trust of clinical partners. The company will continue to build LungOS as the operating system for lung cancer and broader thoracic care.
Optellum is a commercial-stage AI healthcare company headquartered in Oxford, UK, with an office in Houston, Texas, USA. The company is committed to revolutionizing the early diagnosis and treatment of lung diseases by building the LungOS end-to-end AI-driven platform. Its flagship product, the Virtual Nodule Clinic equipped with Lung Cancer Prediction AI, is the world's first FDA-cleared and Medicare-reimbursed Software as a Medical Device (SaMD) solution for AI-driven lung cancer prioritization and diagnostic support. This solution has received FDA clearance, CE-MDR certification, UKCA certification, and TGA approval, and is supported by real-world clinical evidence to reduce time to guideline-recommended treatment and accelerate diagnostic care pathways.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
